Autologous Stem Cell Transplantation (e-bog) af Carella, Angelo
Carella, Angelo (forfatter)

Autologous Stem Cell Transplantation e-bog

435,46 DKK (ekskl. moms 348,37 DKK)
This textbook integrates basic research and clinical aspects underlying the most recent results in those malignant diseases where progress is most effective.Recent evidence shows that higher doses are better in inducing higher cure rates in hematological neoplasias, although myeloblation related to dose intensity can be a limiting factor. The toxicity can now be controlled with autologous marrow …
This textbook integrates basic research and clinical aspects underlying the most recent results in those malignant diseases where progress is most effective.Recent evidence shows that higher doses are better in inducing higher cure rates in hematological neoplasias, although myeloblation related to dose intensity can be a limiting factor. The toxicity can now be controlled with autologous marrow and peripheral blood progenitor cell transplantation, used with or without growth factors. The combination of high dose chemoradiotherapy followed by re-infusion of autologous stem cells constitute a dramatic advance in the treatment of refactory and relapse hematological neoplasias.
E-bog 435,46 DKK
Forfattere Carella, Angelo (forfatter)
Forlag Routledge
Udgivet 26.08.2020
Længde 600 sider
Genrer Oncology
Sprog English
Format epub
Beskyttelse LCP
ISBN 9781000141320
This textbook integrates basic research and clinical aspects underlying the most recent results in those malignant diseases where progress is most effective.Recent evidence shows that higher doses are better in inducing higher cure rates in hematological neoplasias, although myeloblation related to dose intensity can be a limiting factor. The toxicity can now be controlled with autologous marrow and peripheral blood progenitor cell transplantation, used with or without growth factors. The combination of high dose chemoradiotherapy followed by re-infusion of autologous stem cells constitute a dramatic advance in the treatment of refactory and relapse hematological neoplasias.